Objective. ChurgStrauss syndrome (CSS) cardiac involvement is associated with a poor prognosis. Recently cardiac MRI (CMRI) has emerged as a promising technique to detect early CSS cardiac involvement. However, CMRI-detected myocardial delayed enhancement (MDE) could correspond to fibrosis or inflammation. Fluoro-2-deoxyglucose PET (FDG-PET) was previously used in other systemic diseases to distinguish between them. To determine whether the CMRI-MDE detected in CSS patients reflected fibrosis or myocardial inflammation, patients in CSS remission underwent FDG-PET.
Introduction
ChurgStrauss syndrome (CSS), a rare, small-sized vessel necrotizing vasculitis first described in 1951 [1] , is characterized by asthma, eosinophilia and extrapulmonary manifestations. Myocardial abnormalities are found in >50% of autopsied CSS patients [1] . Cardiac manifestations comprise pericarditis, restrictive or dilated cardiomyopathy, myocarditis, arrhythmias and sudden death [26] . Symptomatic cardiomyopathy carries a poor prognosis [7] , is responsible for nearly 50% of the deaths and requires combined therapy with CSs and cytotoxic agents, usually cyclophosphamide (CY) [8] . In a study conducted on 96 patients [9] , the 78-month survival rate was 90% in the absence of symptomatic cardiac manifestations vs 30% in their presence, highlighting the importance of identifying cardiac involvement early during the course of this vasculitis. CSS is considered to be an ANCA-associated vasculitis. However, it was shown that different phenotypes could be observed, depending on ANCA status, thereby suggesting different pathogenic mechanisms [10, 11] . Notably, cardiomyopathy was more frequently observed in ANCA-negative patients, whereas renal manifestations were observed more often in ANCA-positive patients. Cardiac involvement is also one of the items of the Five Factor Score [7] and is associated with a poor prognosis.
Cardiac MRI (CMRI) provides considerable morphological and functional information on a variety of diseases, including systemic and inflammatory diseases, like sarcoidosis [12] [13] [14] . Histological assessment of myocardial delayed enhancement (MDE) was associated with local fibrosis and active myocarditis [15, 16] . Distinguishing between the two signs might be of great importance, as the latter reflects active disease.
Successful imaging of inflammation of the walls of the aorta and large arteries [1520] and of inflamed carotid atherosclerotic plaques [21] with [ 18 F]fluoro-deoxyglucose-PET (FDG-PET) prompted us to explore the possibility of noninvasive assessment of cardiac inflammation in CSS patients. Furthermore, FDG-PET was able to differentiate between active myocardial lesions and fibrosis in patients with systemic disease [22] . To determine whether CMRI-detected MDE in CSS patients is related to inflammation or fibrosis, we simultaneously evaluated patients with CMRI and FDG-PET scans.
Patients and methods
Between March 2004 and February 2006, 20 consecutive CSS patients in clinical remission were enrolled in this study. CSS was classified according to ACR criteria [23] . At CSS diagnosis, all patients had asthma, eosinophilia and extrapulmonary manifestations. The following information was collected for all patients: sex, age, cardiovascular risk factors (cholesterol level, hypertension, tobacco use, diabetes, family history of coronary artery disease), CSS duration, clinical manifestations, history of cardiovascular manifestations and cardiovascular symptoms at the time of CMRI and ECG, echocardiographic and chest X-ray findings. Cardiac involvement was considered to be present when one of the following criteria was met: the patient had or previously experienced cardiac insufficiency, echocardiogram showed heart enlargement or abnormal cardiac function or motion abnormality, abnormal ECG signs defined as complete right or left bundle-branch block, bifascicular block, third-degree atrioventricular block, ventricular tachycardia or pathological Q or ST abnormalities, elevated cardiac troponin I or brain natriuretic peptide (BNP)/N-terminal-proBNP (NT-proBNP). Because CSS affects small-sized vessels, the main coronary arteries are usually normal. Therefore patients with clinical manifestations consistent with coronary artery disease alone underwent coronary angiography.
Pregnant women and patients for whom CMRI was contraindicated were not included in the PET study.
The local ethics committee (Comité de Protection des Personnes, Hô pital Cochin, Paris) approved the study. The Socié té Franç aise de Cardiologie, the French Vasculitis Study Group, Natiralia et biologia and AFM sponsored the study. The subject's written consent was obtained according to the Declaration of Helsinki. The 20 enrolled patients were in clinical CSS remission (BVAS = 0) [24] ; their cardiac manifestations could be related to initial disease or sequelae of a previous relapse.
CMRI protocol
CMRI was performed with a 1.5-T imager Avanto 76 Â 32 SQ (Siemens Medical Solutions, Erlangen, Germany) using a dedicated cardiac, ECG-triggered, phased-array coil. After gradient-echo localizers, T2-weighted images were obtained with a breath-hold, short-axis inversion recovery, black blood fast spin-echo sequence using the following parameters: repetition time 1400 ms (function of RR interval); echo time 47 ms; inversion time 170 ms; 90 flip angle; a 340-mm field of view (function of patient); 256 Â 154 matrix; 8-mm thick section and 4-mm interslice gap.
Functional examinations (Cine-MR) were performed using a breath-hold, short-axis segmented steady-state free precession sequence, with coverage of the whole left ventricle and a single slice per breath-hold. Imaging parameters were as follows: repetition time 2.8 ms; echo time 1.17 ms; 80 flip angle; 256 Â 256 matrix; 380-mm field of view; 6-mm thick section; 8-mm interslice gap. Gadoliniumtetraazacyclododecanetetraacetic acid (DOTA)-enhanced acquisitions were obtained with a left ventricular (LV) short-axis gradient-echo pulse sequence for 50 cardiac cycles during the first-pass of gadolinium-DOTA (perfusion scanning with five images per cycle, i.v. bolus of 0.1 mmol/kg at 5 ml/s) followed by an LV short-axis inversion recovery prepared gradient-echo sequence, one slice per breath-hold, five slices for delayed phase, 10 min after a second 0.1-mmol/kg bolus of gadolinium-DOTA for delayedenhancement imaging, using the following parameters: repetition time 1200 ms (function of RR interval); echo time 1.4 ms; the inversion time to null normal myocardium was determined with a dedicated scouting; 30 flip angle; a 380-mm field of view (function of patient); 256 Â 128 matrix and 6-mm thick section, with no interslice gap. Additional 4-chamber or long-axis views were obtained as needed.
Endocardial borders were outlined on end-diastolic and end-systolic short-axis cine images with dedicated software (Argus; Siemens, Munich, Germany). Volumes and LV ejection fraction (LVEF) were derived by summation of endocardial contours.
Analysis of CMR images
The processed and enhanced hard copy images were analysed side by side by two radiologists and one cardiologist with expertise in contrast-enhanced CMRI, blinded to all information, including the date of the investigation and the patient's name. The myocardium was studied using the 17-segment model [25] . The extent of MDE tissue within www.rheumatology.oxfordjournals.org
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Cardiac MRI and PET for ChurgStrauss syndrome each segment was graded using a 5-point scale [26, 27] scored as follows: 0, no hyperenhancement; 1, hyperenhancement of 125% of the tissue; 2, hyperenhancement of 2650% of the tissue; 3, hyperenhancement of 5175% of the tissue; 4, hyperenhancement of 76100% of the tissue. The CMR images were interpreted as abnormal when the readers independently noted the same abnormal MDE presence, distribution and localization. Myocardial hyperintensity in T2-weighted short T1 inversion recovery sequences was deemed present when described independently by the experts. Interpretation differences among the experts were resolved by consensus.
FDG-PET protocol
These scans were performed at the CEA [Commissariat à l'Energie Atomique, I2BM SHFJ (Service Hospitalier Fré deric-Joliot), Orsay, France] PET facility during the month following CMRI, after confirmation of the absence of CSS symptom occurrence.
Subjects were positioned in an ECAT EXAT HR+ scanner (Siemens, Knoxville, TN, USA), with a 15.2-cm field of view that can simultaneously acquire 63 slices of 2.4 mm thickness. Acquisitions were obtained in 3-dimensional mode after removing the septa. The attenuation coefficients of the patients were measured with three rotating 68-germanium rod sources. The patient was positioned so that his/her heart was at the centre of the tomograph field of view. The heart position in the field of view was adjusted and checked based on a 5-min transmission scan before the examination. Correct positioning was maintained throughout the study by the use of laser beams and skin marks placed on the subject's torso.
To enhance the detection of fibrosis, the FDG-PET studies were performed after glucose loading. Patients consumed a 50-g glucose load 60 min before the scan. After the injection of 4 mCi of FDG, data were acquired in 3-dimensional mode 45 min later. The images were reconstructed using the FORE + 2D filtered back-projection algorithm. Images were corrected for scattered coincidences using a simulation-based method [28] . The images were resliced into series of short-axis, vertical long-axis and horizontal long-axis images, and the standard 17-segment model was applied to define myocardial segments as in the CMRI studies.
PET image analysis
The segments exhibiting MDE on CMR images were reviewed on FDG-PET series independently by two physicians with expertise in cardiac PET imaging. Interpretation differences among the experts were resolved by consensus. Depending on myocardial FDG uptake, its hypofixation, hyperfixation or normal fixation was assigned a score based on the visual analysis.
Blood sample analysis ANCA status was sought for all patients at the time of CSS diagnosis (by IF and ELISA) as were eosinophil count, cardiac troponin I and BNP or NT-pro BNP level.
Statistical analyses
Statistical analyses were performed using StatView software (Abacus Concept, Berkeley, CA, USA). Among the patients with CMRI abnormalities, symptomatic patients were compared with asymptomatic patients. The number of involved segments, the mean MDE score and patients' LVEF were analysed for each group using a nonparametric test (the MannWhitney U-test or Fisher's exact test, when appropriate). P < 0.05 was considered to be statistically significant.
Results
Fourteen patients [eight men and six women; mean (S.D.) age 49 (9) years; mean disease duration 3.5 (2.9) years] with MDE on CMR images, and six patients with normal CMR images [four men and two women; mean (S.D.) age 44 (15) years; mean disease duration 3.5 (5.3) years] underwent FDG-PET scans. The 20 patients had the following CSS manifestations at diagnosis: asthma (n = 19), sinusitis (n = 17), mononeuritis multiplex (n = 15), pulmonary infiltrates (n = 10), skin involvement (n = 6), myalgias/ arthalgias (n = 9) and digestive involvement (n = 5). No significant difference was observed between the 14 patients with MDE on CMRI and the six patients without CMR anomaly (Table 1) .
Patients with CMRI-detected MDE
The demographic, clinical, biochemical and radiological characteristics of the eight men and six women with MDE on CMR images are summarized in Tables 1 and 2 . Ten (71%) of those 14 patients had clinical cardiac manifestations: heart insufficiency (patients 1, 2, 3, 9, 10 and 13) or angina pectoris (patients 5 and 12), which had disappeared at the time of inclusion in the study. Although patients 14 and 8 were always clinically asymptomatic, the former had ECG abnormalities, whereas the latter had both ECG and echocardiographic wall motion anomalies. Coronary angiograms were normal for patients 2, 3, 5 and 10, as were exercise stress tests for patients 4 and 8 in whom coronary artery disease was suspected (Table 3) . Patients 4, 6 and 14 (21%) were ANCA positive. BNP or NT-proBNP was elevated in 5 (36%) patients (1, 10 and 13, and 2 and 9, respectively) with cardiac insufficiency. Patient 9, with high cardiac troponin I levels, also had markedly elevated BNP or NT-proBNP.
Description of the CMR anomalies seen in 14 patients MDE was detected in 48 myocardial segments (mean 3.3 segments/patient) with a transmural myocardial score of 6.9 segments/patient. The mean LVEF was 47%, calculated using cine-MRI sequences. Most enhanced lesions were located in the anterior or anteroseptal wall (segments 1, 7 and/or 8) and were centromyocardial in 10 patients and subepicardial (without coronary distribution) in 4 patients (patients 1, 2, 5 and 9). Patients 1, 3, 6 and 9 had T2 hyperintensity on CMR images.
FDG-PET vs CMRI comparisons for the 14 patients with MDE
Patients 1 and 7 exhibited high myocardial FDG uptake on PET images, 10 patients had low uptake, and patients 6 and 12 had normal PET scans (Table 4 ). Low FDG uptake was seen on the PET scans of 10 patients in the area where MDE was seen on CMR images (Fig. 1 ). Eight of them had clinical cardiac manifestations. For these 10 patients, the mean (S.D.) CSS duration at the time of CMRI was 4 (±3.1) years. Their mean myocardial score was 7.5, their mean number of involved myocardial segments was 3.7 and their mean LVEF was 47.2%. Patients 1, 3 and 9 (33%) had T2 hyperintensity on CMR images. During follow-up, six patients were in complete remission, whereas patients 3, 11, 13 and 14 experienced CSS relapses without new cardiac symptom. High FDG uptake was observed on the PET scans of patients 1 (Fig. 2) and 7 who were symptomatic and asymptomatic, respectively. Their CSS at the time of CMRI had lasted 1 and 4 years, respectively, with respective transmural myocardial scores of 12 and 4, and four myocardial segments involved for each and 31 and 59% of LVEF. All their values were similar to those of patients with low FDG uptake. Patient 1 had T2 hyperintensity on CMR images. During follow-up, patient 1 relapsed without new cardiac symptoms and patient 7 remained in complete remission.
Patients 6 and 12 who had CMRI-detected MDE had normal PET scans. These two patients had only one segment each with MDE, with respective myocardial transmural scores of 2 and 4, and preserved LVEF of 52 and 55%. Patient 12 had angina pectoris, whereas patient 6 was asymptomatic. Patients with normal CMRI Among the six patients without CMRI abnormalities, all were clinically asymptomatic. Patient 18 had an ECG abnormality (paroxysmal atrial fibrillation) and a high cardiac troponine I level at the time of CSS diagnosis. Echocardiogram and coronary angiograms were normal for two of the four patients in whom they had been performed. These six patients with normal CMRI also had normal FDG-PET scans. Patients with abnormal FDG-PET scans had more myocardial segments involved on CMRI than patients with normal FDG-PET scans (P = 0.04).
Discussion
Cardiac involvement is the first cause of death of CSS patients. During follow-up, the majority of patients improve clinically, and normalization of CMR imaging is expected with only visualization of sequelae. At present, because patient assessment does not comprise routine CMRI or other imaging techniques, despite their good abilities to detect active lesions, which could require therapeutic intervention, it is probable that some patients are inaccurately considered to be cardiac involvement free and are therefore undertreated. Pertinently, CMRI can visualize myocardial inflammation and fibrosis. MDE is correlated with histologically proven fibrosis and active myocarditis [15, 16] , but CMRI alone cannot distinguish between theses two lesions. Because the CSS patients included in our study were considered to be in clinical remission, we hypothesized that the MDE seen on CMR images of 14 of them was more likely consistent with myocardial fibrosis. Although 10 of our 14 patients had low FDG uptake, reflecting myocardial fibrosis, 2 patients had high uptake, reflecting myocardial inflammation, and 2 patients had normal FDG binding on FDG-PET scans. Hence the most important finding of this study was the demonstration that, during clinical remission, active myocardial inflammation can persist.
CSS durations before cardiac imaging for patients with active myocardial inflammation were shorter, but not statistically different, than those with myocardial fibrosis. Thus myocardial inflammation can persist after the acute phase of CSS during a progressive phase, with lesion regression or evolution to myocardial fibrosis during a chronic phase.
Indeed, myocardial fibrosis and inflammation might represent two different temporal stages of CSS. This possibility in systemic sarcoidosis was previously raised by Okumura et al. [22] . Based on their study of 22 patients, they demonstrated the accuracy of FDG-PET detection of inflammatory lesions. By combining the results of FDG-PET and 99m
Tc sestamibi SPECT for perfusion assessment, they classified the pathophysiologic process of myocardial involvement at different stages: from high inflammatory activity (high FDG uptake) at an early stage, to low inflammatory activity (low FDG uptake) during a progressive stage and no inflammatory activity at the final stage of fibrosis.
Only one of our two patients with high FDG uptake on PET images had T2 hyperintensity, but the sensitivity of CMRI T2 sequences to detect oedema is known to vary widely, according to the study and the underlying disease. More intriguing is that three patients with low FDG uptake on PET images exhibited T2 hyperintensity on CMR images, which could mean that fibrosis and inflammation might coexist in the same myocardial region. Because of a lack of spatial resolution, FDG-PET might only detect the most predominant component of the pathophysiologic process (fibrosis or inflammation). Moreover, the persistence of myocardial inflammation might reflect an early CSS relapse, as 1 of 2 patients with myocardial inflammation vs 3 of 10 with myocardial fibrosis relapsed during follow-up. However, the small number of patients precludes a definitive conclusion on this point.
One of the two patients with active myocardial inflammation had a history of cardiac insufficiency, and cardiac symptoms were still present at the time of the CMRI; 6 of 10 patients with myocardial fibrosis had a history of cardiac symptoms. Symptomatic cardiac involvement may not only be related to the presence of active myocardial lesions, but might also indicate the extent of initial myocardial damage with persistence or not of cardiac dysfunction.
The six patients with normal CMR image had normal FDG-PET scans. Only one of them had symptomatic cardiac disease. The 14 patients with MDE on CMRI had symptomatic cardiac disease. This finding is in agreement with our previous CMRI study on 20 CSS patients, which showed that CMRI anomalies can indeed be observed in asymptomatic patients, but were more prevalent in those with cardiac symptoms [26] .
The two patients with MDE on CMRI and normal FDG-PET had only one MDE-involved myocardial segment on CMRI and low transmural myocardial scores. These patients had very limited myocardial damage. It is possible that such lesions can be detected by CMRI but not by FDG-PET, because CMRI spatial resolution is better than that of FDG-PET. Patients with abnormal FDG-PET scans had significantly more myocardial segments involved on CMRI than patients with normal FDG-PET.
One limitation is that increased FDG uptake is not specific to inflammation; it might bias result analyses. The only way to diagnose inflammation would be to perform myocardial biopsy. Because this procedure is invasive and has poor sensitivity, we did not use it.
The contribution of new cardiac imaging CMRI and FDG-PET to therapeutic decision making and long-term outcome has not been established. Only one report [29] showed regression of FDG/N-ammonia-PET-detected myocardial involvement after steroid treatment.
To assess the impact of CMR and FDG-PET imaging on CSS outcome and prognosis, results of long-term follow-up of patients will be required, which has been started by our group [26, 27, 30] . Prolonged follow-up could have a therapeutic impact, especially to indicate the need for reintroduction of cytotoxic agents in asymptomatic patients with cardiac imaging anomalies.
Rheumatology key messages
. For CSS patients in remission, CMRI-MDE detected subclinical myocardial lesions that could reflect fibrosis or inflammation. . Cardiac PET might help to distinguish between myocardial fibrosis and inflammation in CSS patients.
